Stock Results: 3/29/07

Trading was halted today for DNDN as the FDA meets to review whether to recommend the company's prostate cancer therapy Provenge for approval. Look for big movement in trading on Friday as the news released this evening, FDA panel votes in favor of Dendreon cancer drug.

RGRP gained 10.28%, SMRL 4.76%